The report provides an overview of the approved therapies for AML, MDS, unmet need and limitations of the current SOC for relapsed and refractory pts. The report highlights the competition and commercial opportunity in pursuing this therapy area - Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them.

Detailed financial and competitive analysis of the companies leading in the race to launch new therapies for this indication - Ambit Biosciences, Onconova Therapeutics, SymBio Pharma, and Celgene are available as a separate or with the full report. Key M&A activities that have taken place in this area in the last 5 years and a list of products in early /late stages of development available for in-licensing are highlighted in the report. This report is built using primary and secondary research data and in-house proprietary database.

Table of Contents.

Executive Summary

2. Investment Drivers of The Select Companies Covered
3. Myelodysplastic syndrome (MDS)
3.1 Disease Overview
3.2 Unmet Need
3.3 Current Standard of Care
3.3.1 Supportive Care
3.3.2 Low-Intensity Therapy
3.3.3 High-Intensity Therapy
3.3.4 Recurrent/ Refractory or relapsed MDS
4. Acute Myelogenous Leukemia (AML)
4.1 Disease Overview
4.2 Current Standard of Care
4.2.1 AML pts younger than 60 years
a Induction Therapy
b Post-remission/ consolidation therapy
4.2.2 AML pts Older than 60 years

List Of Figures :

* Ambit Biosciences - MONOTHERAPY RESPONSE RATES (CRc) IN AML

* Ambit Biosciences - QUIZARITINIB - PhIIb COMPARABLE EFFICACY WITH LOWER DOSES

* Ambit Biosciences - QTC PROLONGATION AT VARIOUS DOSES OF QUIZARTINIB

* Ambit Biosciences - LONG TERM SURVIVORS IN PHASE 2 - TREATED WITH QUIZARTINIB

* Ambit Biosciences - QUIZARTINIB MARKET OPPORTUNITY IN US IN AML

* Ambit Biosciences - OVERALL SURVIVAL FOR AML PTS LESS THAN 60 YEAR OLD WITH FLT3 ITD MUTATION

* Ambit Biosciences - PROPOSED PHIII TRIAL OF QUIZARTINIB

* Onconova Therapeutics - PHIII TRIAL DESIGN - ONTIME

* Onconova Therapeutics - ITT ANALYSIS: SURVIVAL DATA FOR REFRACTORY MDS PTS

* Onconova Therapeutics - BEST BONE MARROW (BM) RESPONSES AFTER RIG. IV

* Onconova Therapeutics - PHII TRIAL DESIGN - ONTARGET

* Onconova Therapeutics - PHIII TRIAL DESIGN - ONTRAC

To order this report:

http://www.researchonglobalmarkets.com/treating-refractory-hematological-malignancies.html

Email: [email protected]
US: +1 866 325 7446
UK: +44 203 514 2363
India: +91 22 4098 7600
SOURCE: Researchonglobalmarkets.com

RELATED LINKS
http://industry-research-report.blogspot.in/2014/01/treating-refractory-hematological.html